Our findings suggest that these candidate Col10a1 transcriptional regulators, including Tbx5, are potential therapeutic targets in collagenopathy and skeletal diseases associated with abnormal Col10a1 expression and chondrocyte hypertrophy. Here, COL10A1 is linked to bone disorder.